IGF-I and -11 are peptides that promote the growth and differentiated function of many tissues (1-3). These 7.5-kD peptides are found in serum and other body fluids at a higher MW. tightly bound by a family of at least six IGFBP (4) (5) (6) (7) (8) (9) (10) . Most IGF circulate at -150 kD (high-MW serum fractions) in association with a 41-or 38-kD form of IGFBP-3 and an acid-labile ( t u ) subunit (10) (11) (12) , whereas the remaining IGF circulate at -35 kD (low-MW serum fractions) bound to some or all of the six IGFBP. Because IGFBP in the low-MW fractions are in molar excess of IGF, they provide unsaturated sites for IGF binding (10, 13) .
The 41-and 38-kD forms of intact, differentially glycosylated IGFBP-3 are the major serum lGFBP during extrauterine life. Levels of these two IGFBP-3 forms, and also of the 150-kD complex, seem to vary directly with the GH status of the individual (10, 14) . This suggests an anabolic role for the 41-and 38-kD IGFBP-3 forms. perhaps as part of this 150-kD complex. In fact, these 41-and 38-kD IGFBP-3 forms can potentiate IGF action under some, but by no means all. experimental conditions (15) (16) (17) (18) .
Two additional IGFBP are well characterized. IGFBP-1 and IGFBP-2 are nonglycosylated proteins of 28 and 33 kD, respectively. Both migrate in low-MW serum fractions and may contribute significantly to the IGF-binding capacity of serum; this is especially true before puberty, when levels of both proteins are highest (I 9.20) . IGFBP-1 levels and serum 1GF-binding capacity are each high during GH deficiency and fall with GH therapy: in rats, IGFBP-I and -2 levels are also high in growth-failure states such as undernutrition and diabetes mellitus, and levels fall in the presence of insulin (I 0. 13. 2 1-24). Such data suggest that IGFBP-I and -2 may block the anabolic effects of IGF peptides in vivo. In fact, IGFBP-I and -2 inhibit IGF action under most (25) (26) (27) . but not all (28) . experimental conditions. apparently by competing with IGF receptors for IGF binding (25, 26) .
The marked growth failure of children with CRF has suggested a need to characterize the IGF system in uremia. As in GH deficiency, CRF is associated with I ) a shift of IGF from 150-to 35-kD serum fractions: 2) higher serum IGFBP-I levels; and 3) increased capacity of serum to bind IGF peptides (10, 19, 29- IGFBP, IGF-binding protein 3 1). However, CRF differs from GH deficiency in that IGF levels MW, molecular weight are not low, and IGFBP-3 levels are high. in CRF serum when CRF, chronic renal failure measured by RIA (10, 19. 30-34) . Blum responsible for the increased IGF-binding capacity of CRF serum. and that this excess of unsaturated binding sites may inhibit IGF action in viva. including a possible inhibition of skeletal growth. The significance of an almost complete absence of 150-kD complex was not addressed by Blum 6.f 01.; presumably, IGFBP-3 not trapped in the 150-kD complex would more easily enter extravascular spaces to inhibit IGF action.
In past studies, we have also found by RIA that serum IGFBP-3 levels are high in CRF children ( 19) . However. we did not find high levels of the 4 1-and 38-kD IGFBP-3 forms when CRF and normal sera were transferred to nitrocellulose membranes and probed with ["51]IGF. a method known as ligand blotting. Also, further studies using this technique indicated that most of the 41-and 38-kD IGFBP-3 forms present in the serum of CRF children migrated with the 150-kD serum complex and not at a lower MW (29) . The present studies attempted to resolve the above discrepancies by further characterizing the IGFBP-3 forms found in CRF serum.
MATERIALS A N D METHODS
t'o~)tides. Recombinant IGF-I and IGF-11 were obtained from Amgen (Thousand Oaks, CA) and from Eli Lilly Co. (Indianapolis, IN), respectively. Recombinant IGFBP-3 was a gift of Biogrowth, Inc. (Richmond, CA). These peptides were iodinated by a modification of the chloramine-T method (20) . IGFBP-I was purified from amniotic fluid and was iodinated as described previously (19. 27) .
[1251]a-subunit was kindly provided by Dr. R. C. Baxter (Sydney, Australia). In some experiments, ["Thr] IGF-I labeled with lZ51 ([1251]IGF-1) was purchased from Amersham (Arlington Heights. IL).
Serlrrn Surnples. The experimental protocol was approved by the Baylor Institutional Review Board; informed consent was obtained from all patients before entry. Serum was obtained from six prepubertal children with CRF and from six age-and gender-matched prepubertal healthy children; the characteristics of these groups of children have been reported (29) . In addition, serum was obtained from seven adolescents with CRF requiring chronic hemodialysis therapy (age 17 + 2 y, mean f SD) and from seven age-and gender-matched healthy adolescents (age I6 + 2 y). All individuals were fasted for at least 3 h before obtaining serum samples: hemodialysis patients had their blood drawn before a regularly scheduled dialysis treatment. Blood samples were clotted at 22°C for 0.5 to 2 h and centrifuged, and the serum was then stored at -70°C until assay.
Sizc~-c~xcllrsion Chrornatograph.~. Sephucrvl 9300. Pooled serum samples (0.5 mL), composed of equal aliquots from seven healthy adolescents or from seven adolescents with CRF, were individually chromatographed at pH 7.4 on a 0.9 x 120 cm Sephacryl S-300 column as described previously (29) . Individual 2-mL column fractions were assayed for IGFBP by ligand blotting, and for IGFBP-I and IGFBP-3 by specific RIA.
S~phadex G-50. IGF in the 2-mL fractions from the Sephacryl S-300 column were separated from IGFBP by acid chromatography as described previously (31) and then assayed by specific RIA for IGF-I and IGF-11. P-66. In experiments characterizing the ability of intact serum IGFBP-3 to form the 150-kD complex, CRF and normal serum pools identical to those described above were separated on a Pharmacia K 25/45 column packed with P-60 (Bio-Rad, Richmond, CA). The column was eluted at 22°C by running 0.5 M acetic add. 75 mM NaCl as mobile phase at 10 mL/h. Individual 2-mL fractions were collected, and these fractions were then neutralized and assayed for the presence of IGFBP by ['251 (36) . Antiserum against human IGFBP-3 was a gift of Dr. W. F. Blum (Tubingen, Germany) (37) . These three antibodies were used to immunoprecipitate IGFBP directly from serum and serum fractions, and also to immunoprecipitate IGFBP from these sources that had first been cross-linked to ['"I]IGF-I as described previously (20) . Briefly, Staphylococcus protein-A (Pansorbin, Calbiochem, Ldolla, CA) was washed in 50 mM Tris-HC1, pH 7.4, and resuspended in the original volume with Tris buffer. Nonspecific precipitation by Pansorbin was eliminated by preincubating samples with 50 pL Pansorbin for 2 h at 4°C on a rotating mixer; the Pansorbin was then removed by centrifugation.
For each immunoprecipitation, 50 pL Pansorbin were incubated for 4 h at 4°C with 1 pL IGFBP-3 antiserum, 5 pL IGFBP-2 antiserum or 5 pL IGFBP-1 MAb; Pansorbin used with IGFBP-1 antibody was first coated with rabbit anti-mouse IgG (Organon Teknika Corp., West Chester, PA). After centrifugation, the antibody-Pansorbin pellets were washed, resuspended, and incubated with the prepared samples overnight at 4°C on a rotating mixer. Immunoprecipitates were pelleted by centrifugation and washed three times with 50 mM Tris-HC1, pH 7.4, containing 0.5% Triton X-100. Samples to be used in [1251]IGF ligand blots were resuspended in 75 pL nonreducing sample buffer, and crosslinked samples were resuspended in the same buffer containing 5% P-mercaptoethanol. After boiling for 5 min, samples were centrifuged and their supernatants then electrophoresed on a 12% polyacrylamide gel.
/1251]IGF ligand blotting. ['251]IGF ligand blotting was performed as described previously (29) and is based on the method originally described by Hossenlopp er al. (38) . Briefly, serum. serum fractions. and immunoprecipitated IGFBP were electrophoresed on a 12% SDS polyacrylamide gel under nonreducing conditions. Separated proteins were transferred to nitrocellulose (0.45-~m pore size), using a Biotrans semidry electrophoretic transfer unit (Gelman Sciences, Ann Arbor, MI) and Towbin buffer (25 mM Tris/192 mM glycine/20% methanol). Nitrocellulose membranes were blocked in succession with 3% Nonidet P-40 (Sigma), 1 % BSA (Sigma), and 0. I % Tween-20 (Sigma) in Tris-saline, pH 7.4, and then incubated overnight with approxi-
After washing and drying, filters were exposed to film for 1 to 3 d.
RIA. For IGF-I and IGF-I1 RIA, individual serum fractions were acid chromatographed to separate IGF from IGFBP: after acid chromatography, the fractions containing IGF were pooled, lyophilized, reconstituted, and assayed as described previously (20) . IGF-I antiserum was provided by Drs. L. E. Underwood and J. J. Van IGFBP-1 and IGFBP-3 levels were measured directly in serum and serum fractions. The IGFBP-3 RIA was performed as described previously (20) . using the same antiserum as was used for immunoprecipitation; radioligand consisted of [12SI]IGF-I covalently bound to IGFBP-3 (34) . The IGFBP-I RIA was also performed as described previously, using antiserum raised to human IGFBP-I purified from human HEP G2 cells ( 19) .
RESULTS
/'*']IGF Ligand Blotting qf Whole-Serum Samples. Individual sera from age-matched CRF and normal children and pooled CRF and normal sera from these same children were compared by ['2SI]IGF-I ligand blot. As shown in Figure 1 , 41-and 38-kD IGFBP-3 forms were present in sera of CRF children throughout the prepubertal years, and in general these levels were not different from levels present in the sera of normal children. In contrast. levels of a 33-kD IGFBP and a 28-kD IGFBP were elevated in CRF sera. Also, CRF sera usually had a diffuse region of ['251] IGF-I binding between 28 and 22 kD.
Similar studies were performed on sera from seven adolescents with CRF and seven age-matched controls, using Immunopr~~cipitation of IGFBP,from Whole-Serum Samples. T o identify some of these IGFBP, sera were separately pooled from the seven CRF and seven normal adolescents and subjected to immunoprecipitation using antisera to human IGFBP-3, human IGFBP-I , and rat IGFBP-2. As shown in Figure 3 3 antiserum precipitated only the 41-and 38-kD IGFBP. and equal amounts of these bands were precipitated from CRF and normal serum. In contrast, the IGFBP-2 antiserum precipitated primarily the 33-kD IGFBP, and more of this band was precipitated from CRF than from normal serum. The IGFBP-1 antiserum precipitated primarily a 28-kD IGFBP from CRF serum, whereas none of this, or any other, IGFBP was precipitated from normal serum. Sera from the 14 adolescents were used in all remaining studies to avoid the age-related variability in IGF and IGFBP levels found in prepubertal populations.
RIA of IGFBP Levels in Wliolc Serum. Although IGFBP-3 levels were not elevated in CRF serum by ligand blot, levels were significantly higher in CRF serum when measured by RIA: Table  1 shows that IGFBP-3 levels in CRF sera were -50% higher than normal. RIA of pooled sera also found a -50% increase in CRF (15.6 Pg/mL) over normal (9.3 Pg/rnL) levels, suggesting the pools to be representative of the two groups. IGFBP-I levels by RIA were also quite elevated in sera from adolescents with CRF.
f'251/IGF Ligand Blotting of Size-Fractionated Serum. To in- Fig. 4. [i251]1GF-II ligand blot of normal (top) and CRF (bottom) serum fractions after these sera were separated by neutral size-exclusion chromatography. Pooled normal (NL) or CRF sera (0.5 mL) were separated on a 0.9 x 120 cm column of Sephacryl S-300: 2-mL fractions were collected. vestigate the discrepancy between IGFBP-3 levels in CRF serum assayed by ligand blotting and by RIA, equal aliquots of pooled CRF or normal sera were each size-fractionated by neutral gel filtration over a column of Sephacryl S-300, after which individual column fractions were studied for their IGFBP content by ligand blotting. Figure 4 ["51]1GF-I/IGFBP-3 led to formation of a 150-kD complex; prior acidification of normal serum (lane 4 ) . which destroys a-subunit activity. prevented formation of this complex. These results suggest that CRF serum contains functional a-subunit. In Figures  5 B and 5C. ["51]a-subunit was used to reconstruct the 150-kD complex. Figure 5B RIA of'IGFBP and IGF Levels in Size-Fractionated Serum. Individual CRF and normal serum fractions were assayed for IGFBP-3 by RIA (Fig. 6) . Although IGFBP-3 levels in the 150-kD complex are slightly higher in CRF serum, the greatest difference between CRF and normal samples is found in the low-MW serum fractions, where CRF has a second IGFBP-3 peak that is barely seen in normal serum. This peak could account for the higher IGFBP-3 levels detected in CRF serum by RIA. An IGFBP-1 RIA was performed on these same fractions: IGFBP-1 levels were undetectable in normal serum fractions, but were detectable in fractions 29 to 32 of CRF serum, where they peaked in fraction 3 1.
When individual CRF and normal serum fractions were assayed using IGF-I and IGF-I1 RIA, each IGF had a biphasic distribution in CRF serum similar to that for IGFBP-3 (data not presented). In normal serum, 86% of IGF-I and IGF-I1 were found in the high-MW, 150-kD complex (fractions 24-29.5), with the remaining 14% in the low-MW size range (fractions 29.5-34). In contrast, only 56% of the IGF peptides were found in the 150-kD complex of CRF serum, with 44% present in the low-MW size range. Total IGF-I levels were comparable between CRF and normal sera, whereas total IGF-I1 levels in CRF sera were 30% higher than normal.
Immunoprecipitution of' IGFBP from Size-Separated Serum Samples: Detection by /1251]IGF Ligand Blotting. Although low-MW fractions of CRF serum contain a large amount of IGFBP-3 by RIA, ['2SI]IGF ligand blotting of these same fractions fails to reveal the usual 41-and 38-kD IGFBP-3 forms. To test whether IGFBP-3 forms smaller than 41 and 38 kD. perhaps representing proteolytic fragments, were present in these low-MW fractions, volumes of the high-(1 50 kD) and low-(35-kD) MW IGFBP-3 peaks, which had equal amounts of IGFBP-3 by RIA, were incubated with IGFBP-3 antiserum. This antiserum precipitated the usual 41-and 38-kD IGFBP-3 forms from the high-MW (150-kD) peak, but precipitated barely detectable amounts of the 41-and 38-kD forms and no other IGFBP from the low-MW (35-kD) peak (data not presented). In contrast, IGFBP-2 and IGFBP-I antisera precipitated their usual 33-and 28-kD IGFBP, respectively, from the low-MW CRF fractions, indicating the integrity of the immunoprecipitation procedure.
Immunoprecipitution of IGFBP from Size-Separated Serum Samples; Detection by /1251]IGF Cross-Linking. In a further attempt to identify low-MW IGFBP-3 forms in CRF serum, the low-MW fractions of pooled CRF and normal sera were crosslinked with ['251]IGF-I and then immunoprecipitated with the antibodies to human IGFBP-3, human IGFBP-I, and rat IGFBP-2. As is shown in Figure 7 , the IGFBP-3 antiserum precipitated 19-and 14-kD IGFBP (after subtracting the 7-kD mass of the cross-linked IGF-I) from the low-MW fractions of CRF sera: much smaller amounts of these same IGFBP were precipitated from the low-MW fractions of normal sera. IGFBP-1 and IGFBP-2 antisera also precipitated more of their usual IGFBP forms from the CRF than from the normal sample: in this experiment. IGFBP-2 was barely detectable in the CRF sample and was not found in the normal sample. DISCUSSION By ['251]IGF ligand blot, the concentration and size distribution of the 4 1 -and 38-kD IGFBP-3 forms does not appear to be different between CRF and normal sera from adolescents and children; these IGFBP are primarily found in the 150-kD serum complex in each case (29, present study). The reason for elevated RIA levels of IGFBP-3 in the serum of adolescents with CRF appears to be an excess of IGFBP-3 forms, some or all of which are 19-or 14-kD in size, which circulate at low MW rather than as part of the 150-kD IGF-IGFBP-a subunit complex. Blum pr al. (33) also found elevated RIA levels of IGFBP-3 in the serum of CRF children and determined that part of this increase was due to an RIA peak at 25 kD, which was felt to consist of IGFBP-3 fragments. In contrast to our past (29) and present studies. however, their study found that intact IGFBP-3 did not migrate at 150-kD during size exclusion chromatography, but instead migrated at 55 kD, roughly the size of IGFBP-3 bound to an IGF peptide but without an a-subunit. In our studies, Sephacryl S-300 chromatography showed that the 41-and 38-kD IGFBP-3 forms of CRF serum migrated with aldolase at 158 kD, three fractions ahead of the 41-and 38-kD forms of purified human IGFBP-3 (29, present study). In the present work, the 41-and 38-kD forms in CRF sera also comigrated with the same IGFBP-3 forms in normal sera, which would be expected if the IGFBP-3 forms in CRF sera were part of the typical 150-kD serum complex. Additional studies presented here show that each of the three components of the 150-kD complex (IGFBP-3. IGF, CRF SERUM I NL SERUM 35 kD peak 35 kD peak and a-subunit) are present in CRF serum in a form that can be incorporated into this complex. Thus, significant amounts of 150-kD complex seem to be present in the CRF sera studied here. The differences between these observations and those of Blum ct 01. may be explained by differences in patients studied; also, if the association between the a-subunit and the IGF-IGFBP-3 complex is decreased in the 150-kD complex of CRF serum, then the 150-kD complex may remain intact during size separation with Sephacryl S-300 but not with the method used by Blum (q ul. Additional studies are needed to characterize both the function of the 150-kD complex and any changes in this complex brought about by exposure to the uremic milieu.
The studies presented here confirm the finding of Blum et al. ]IGF ligand blots presented here suggest that IGFBP-2 levels in CRF, but not normal, serum contribute significantly to the total IGFBP pool. The finding that CRF adolescents have high serum IGFBP-1 levels by immunoprecipitation and by ligand blot is consistent with high IGFBP-1 levels found in this same serum by RIA and is also consistent with past reports of high RIA levels of IGFBP-1 in serum from CRF children and adults (19, 33, 39, 40) . In the present study, IGFBP-I levels are '/60 of the levels of IGFBP-3 in serum of CRF adolescents. suggesting that IGFBP-I does not contribute significantly to the total serum IGFBP pool in adolescents with CRF.
Because CRF serum has an excess of IGFBP relative to IGF peptides, it has been suggested that these excess IGFBP may impair IGF-mediated effects in vivo, including linear growth, and that their excess implies decreased production of IGF peptides (19, 30, 33, 41) . Initially, IGFBP-I was identified as a potential inhibitor of IGF action in CRF (19) , but recently it has been suggested that low-MW IGFBP-3 forms are more likely to be inhibitors, inasmuch as their serum RIA levels are much higher than those of IGFBP-1 (33). If IGFBP-3 is a growth inhibitor in CRF children, then IGFBP-3 levels might be expected to fall during therapy, which improves the growth of these individuals. However, although Hokken-Koelega et a/. (42) found that serum RIA levels of IGFBP-1 fell in CRF children who grew dramatically during GH therapy, serum RIA levels of IGFBP-3 were found to actually rise in these children. These data are still consistent with a role for IGFBP-3 forms as growth inhibitors if one considers that serum IGF-I levels increased to a greater degree than IGFBP-3 levels in the above study. Thus, a molar excess of IGFBP-3 (and other IGFBP) relative to IGF peptides in the untreated CRF state should result, at equilibrium, in less free IGF-I; in contrast, GH treatment may well decrease the molar excess of IGFBP-3 (and other IGFBP) by increasing the rate of IGF-I production, thereby shifting the equilibrium toward a higher level of free, bioactive IGF-I and limiting the amount of free, unsaturated IGFBP. An alternative explanation is that IGFBP-3 fragments potentiate IGF-I effects and are present in CRF to augment compromised IGF-I function. and that GH stimulates growth and anabolism in CRF patients, at least in part, by increasing levels of IGFBP-3 fragments. Indeed, this latter possibility is supported by studies showing that IGFBP-3 fragments can potentiate IGF-I action under certain circumstances (43) . Unfortunately, neither unsaturated IGFBP levels nor levels of IGFBP-3 fragments were measured by HokkenKoelega el al.
Blum et al. (33) hypothesized that the greater IGF binding capacity of CRF sera, due apparently to excess IGFBP-3 forms, was responsible for the lower incorporation of sulfate into porcine cartilage by these sera. To test this, they first removed unsaturated IGFBP from CRF and normal sera by passing each through an IGF-I1 affinity column. They then tested the bioactivity of each serum sample and found that sulfate incorporation by CRF sera was closer to normal after removal of unsaturated serum IGFBP.
suggesting that excess IGFBP-3 forms in CRF sera inhibit, rather than potentiate, IGF action. The pattern of IGF binding in the cross-linking studies presented here suggests that 19-and 14-kD IGFBP-3 clearly contribute to the increased IGF binding capacity of CRF serum, but indicate that IGFBP-1 and IGFBP-2 also contribute significantly to this pool of unsaturated IGFBP. These data are consistent with a number of studies that show that excess unsaturated IGFBP, including IGFBP-1. -2, and -3, can inhibit IGF-mediated mitogenic and metabolic events in many tissues and cell lines (15, 16, (25) (26) (27) (28) . Of particular interest to this discussion is the effect of IGFBP-I on growth plate cartilage:
Burch et ul. (27) found that purified, unsaturated IGFBP-I inhibited both basal and IGF-I-mediated growth ofchick embryo pelvic cartilage and that the inhibition was overcome with excess IGF-I. In this model, basal cartilage growth was also inhibited with antiserum to human IGF-I, suggesting that IGFBP-I blocks cartilage growth by competing with the IGF-I receptor for IGF-I binding. The fact that unsaturated IGFBP present in excess in CRF serum can inhibit IGF action is only important if levels of these IGFBP are increased in CRF tissues. Although this has not yet been demonstrated for any IGFBP, past work has shown that IGFBP such as IGFBP-I , IGFBP-2, and a 20-kD form of IGFBP-3 readily migrate into lymph fluid (44) ; thus, these low-MW IGFBP have access to interstitial spaces, and their levels may well be elevated in the tissues of CRF individuals. The 19-and 14-kD IGFBP-3 proteins present in CRF serum are likely to be proteolytic fragments of the 41-and 38-kD forms, because only one IGFBP-3 mRNA transcript has been identified and there is only one copy of the IGFBP-3 gene in the human genome (6, 20, 45, 46) . In addition, these 19-and 14-kD IGFBP-3 forms are similar to proteolytic fragments of IGFBP-3 found in pregnancy serum (47, 48) . Pregnancy serum contains an enzymatic activity that digests the 41-and 38-kD IGFBP-3 forms present in the 150-kD serum complex, resulting in IGF-binding fragments of 27. 19, and 13 kD; purified 4 1 -and 38-kD IGFBP-3 forms are also digested by this serum activity. The 19-and 13-kD fragments from pregnancy serum are similar to the 19-and 14-kD IGFBP-3 forms in CRF serum in that they are easily detected by ['251]IGF cross-linking but not ligand blotting (48) . It is unlikely that these low-MW IGFBP-3 forms are an artifact of the cross-linking reaction, inasmuch as the 19-and 14-kD forms do not appear when either purified IGFBP-3 or IGFBP-3 released by acid chromatography of the CRF 150-kD complex are cross-linked to IGF peptides (16, 29, 48) . It also seems unlikely that the 19-and 14-kD IGFBP-3 forms accumulate in CRF serum by the same proteolytic process that occurs in pregnancy serum, because CRF serum. unlike pregnancy serum, has normal levels of the 4 1-and 38-kD IGFBP-3 forms detected by [1251]IGF-I ligand blotting. Quite possibly, the 19-and 14-kD IGFBP-3 forms accumulate in CRF serum due to decreased renal clearance.
The 19-and 14-kD proteins could be amino-and/or carboxyterminal fragments of IGFBP-3; Spencer ct a/. (43) isolated a 15-kD IGFBP-3 form that binds IGF and contains the IGFBP-3 amino-terminal sequence, whereas Wang c.t a/. (49) isolated a carboxy-terminal IGFBP-2 fragment that binds IGF. Thus, purification of the 19-and 14-kD IGFBP-3 forms will give insight into where IGFBP-3 proteins bind IGF peptides and will also allow functional studies of these low-MW regulatory proteins that accumulate in CRF serum.
